Target: Ret | Disease State: Cancer

Introduction / Brief Description

LOXO-292 is an oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types with varying frequency. Genomic alterations in RET kinase, which include fusions and activating point mutations, lead to overactive RET signaling and uncontrolled cell growth. LOXO-292 is currently being studied in the global LIBRETTO-001 Phase 1 trial.

In July 2013, Array initiated a multi-year license and collaboration agreement with Loxo Oncology for certain Array-invented compounds including Larotrectinib / LOXO-101, a Trk inhibitor, LOXO-292 and LOXO-195, a Trk inhibitor.

Loxo will fund Array's research and will be responsible for target selection and conducting clinical trials. Array has earned $7 million in milestone payment for the advancement of the programs. Array is eligible to receive up to $429 million in additional milestone payments and to receive royalties on sales of any resulting drugs.

Clinical Trials

To learn more about LOXO-292 clinical trials, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.